Pfizer, in collaboration with German mRNA company BioNTech, has already begun the clinical trials for the BNT162 vaccine program in the U.S. and Europe to prevent the effect of the virus to the maximum possible extent.Original Article
COVID-19 Vaccine To Be Ready By October, Global Pharma Ace Claims
